CUE Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Benzinga - Mentions: PHAR AGIO PMN KZIA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

13 days ago - By: Zacks Investment Research - Mentions: MRSN

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

13 days ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

18 days ago - By: Zacks Investment Research - Mentions: CRVO

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

19 days ago - By: Zacks Investment Research - Mentions: PBYI

Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates

20 days ago - By: Zacks Investment Research - Mentions: ADPT

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

8 months ago - By: Benzinga

What's Going On With Cue Biopharma Shares Tuesday?

2 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

3 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

3 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

4 months ago - By: Zacks Investment Research - Mentions: FENC

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: Zacks Investment Research - Mentions: SCPH

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

5 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

5 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

7 months ago - By: Zacks Investment Research - Mentions: FENC

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

7 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

7 months ago - By: Zacks Investment Research - Mentions: MXCT

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

7 months ago - By: Zacks Investment Research - Mentions: IRD

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline

7 months ago - By: Zacks Investment Research - Mentions: HRMY

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

7 months ago - By: Yahoo Finance - Mentions: MU REGN RGEN NVDA ...

Jim Cramer on Micron (MU): “No Catalyst, But You’re Buying Near the Low End”

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma Announces Proposed Public Offering

8 months ago - By: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

8 months ago - By: Cue Biopharma, Inc.

CUE BIOPHARMA INC (CUE) Stock News

CUE Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

What's Going On With Cue Biopharma Shares Tuesday?

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

Jim Cramer on Micron (MU): “No Catalyst, But You’re Buying Near the Low End”

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma to Host Business Update Call and Webcast

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases